

Drugs in R&D.
DUP - General Collection
W1 DR893TC
v. 5, no. 6
2004

DrugsTM *in* R&D

2004, Vol. 5, No. 6 (pp. 313-369)
ISSN: 1174-5886

Research Perspectives
Antineoplaston A10 and AS2-1
D-003
Nonsteroidal Anti-Inflammatory Drugs



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

adis
INTERNATIONAL

Par Pharm., Inc.
Exhibit 1115
Par Pharm., Inc. v. Novartis AG
Case IPR2016-01479

Contents

Acknowledgement		313-314
Original Research Article	Phase II Study of Antineoplaston A10 and AS2-1 in Children with Recurrent and Progressive Multicentric Glioma: A Preliminary Report <i>SR Burzynski, RA Weaver, RI Lewy, TJ Janicki, GF Jurida, BG Szymkowski, MI Khan, M Bestak</i>	315-326
Short Communication	<i>In Vitro</i> Effects of Selective and Non-Selective Nonsteroidal Anti-Inflammatory Drugs on the Frequency of Sister Chromatid Exchanges <i>S Öztürk, BG Köseoglu, H Koçak, S Palanduz, K Çefle, H Erkal</i>	327-330
	Effect of D-003 on a Subconvulsive Dose of Kainic Acid in Rats <i>D Carbajal, M Noa, V Molina, R Más, M de L Arruzazabala</i>	331-336
Adis R&D Profile	Gadofosveset: MS 325, MS 32520, Vasovist, ZK 236018	339-342
	Icatibant: HOE 140, JE 049, JE049	343-348
	Omeprazole/Antacid-Powder Suspension – Santarus: Omeprazole/Sodium Bicarbonate Powder – Santarus, SAN 05	349-350
	Palifermin: AMJ 9701, KGF – Amgen, Recombinant Human Keratinocyte Growth Factor, rHu-KGF	351-354
	Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E	355-358
	Tamibarotene: AM 80, Retinobenzoic Acid, Tamibaro	359-362
	Temsirolimus: CCI 779, CCI-779, Cell Cycle Inhibitor-779	363-367
	Testosterone Undecanoate – Schering AG	368-369

Register for the free Adis Electronic Table of Contents E-Mail Alert Service today at www.adisonline.info

Drugs in R&D is indexed in Index Medicus/MEDLINE, EMBASE, the Chemical Abstracts Service (CAS) and International Pharmaceutical Abstracts (IPA). Individual articles are available through the ADONIS document delivery system and are available

International Editorial Board

- G. Amsden**, Cooperstown, NY, USA
S.E. Bellibas, Nutley, NJ, USA
E. Beghi, Milan, Italy
S. Bloomfield, Cincinnati, OH, USA
A. Bryskier, Paris, France
E. Christophers, Kiel, Germany
M.J. Eadie, Brisbane, QLD, Australia
D. Furst, Seattle, WA, USA
L.C. Groop, Malmö, Sweden
F. Horak, Vienna, Austria
B.D. Kahan, Houston, TX, USA
R. Kawamori, Tokyo, Japan
M.G. Kris, New York, USA
M. Lader, London, UK
K. McCormack, Leighton Buzzard, UK
J. Hamilton-Miller, London, UK
T. Morgan, Melbourne, VIC, Australia
G. Morris III, Milwaukee, WI, USA
G. Moyle, London, UK
P. Nathan, Melbourne, VIC, Australia
D.J. Nutt, Bristol, UK
E. Perucca, Pavia, Italy
S.C. Schachter, Boston, MA, USA
M.A. Smith, Cleveland, OH, USA
F. Vajda, Melbourne, VIC, Australia
C.J. van Boxtel, Amsterdam,
The Netherlands
H. van Leusden, Oosterbeek,
The Netherlands
J. Wilson, Shreveport, LA, USA
V. Wong, Hong Kong
N. Yuen, Apex, NC, USA

Aim and Scope: The aim of *Drugs in R&D* is to provide timely information on: (i) emerging drug classes; and (ii) new treatments for specific disorders. Original research from all phases of clinical development is included, with a strong link to clinical practice. Healthcare decision-makers are thus provided with clinically applicable knowledge about the likely place in therapy of a drug.

Journal issues comprise:

- Original research, including clinical trials with an emphasis on optimum clinical use and pharmacokinetic and pharmacodynamic studies in patients and healthy volunteers.
- R&D drug profiles including: (i) key drug properties; (ii) drug development phase by country and indication; (iii) analysis of commercial potential.

All articles are subject to peer review by international experts.

Publication Manager: Lorna Venter-Lewis

Editorial Office and Inquiries: Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand. Information on the preparation of manuscripts will be provided to authors.

E-mail: DrugsR&D@adis.co.nz

<http://www.adis.com/rdd>

Drugs in R&D (ISSN 1174-5886) is published bi-monthly by Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand. The annual 2005 institutional subscription price for print and online is \$US735 and for online only is \$US725. The personal subscription price for print and online is \$US230 and for online only is \$US225. All online subscriptions include access to online archived articles. Further subscription information is given at the back of each issue.

Policy Statement: Although great care has been taken in compiling the content of this publication, the publisher and its servants are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not necessarily reflect the views of the Publisher, Editor or Editorial Board.

Copyright: © 2004 Adis Data Information BV. All rights reserved throughout the world and in all languages. No part of this publication may be reproduced, transmitted or stored in any form or by any means either mechanical or electronic, including photocopying, recording, or through an information storage and retrieval system, without the written permission of the copyright holder.

The appearance of the code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for the personal or internal use of specific clients. This consent is given provided that the fee of \$US31 per copy is paid directly to the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, Massachusetts 01923, USA, for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

Temsirolimus

CCI 779, CCI-779, Cell Cycle Inhibitor-779

Abstract

Wyeth (formerly American Home Products) is developing temsirolimus [*Cell cycle inhibitor-779, CCI 779*], an ester analogue of sirolimus, for the treatment of cancer, multiple sclerosis and rheumatoid arthritis. Temsirolimus binds to the cytosolic protein, FKBP, which subsequently inhibits mTOR (mammalian target of rapamycin). Inhibition of mTOR blocks a number of signal transduction pathways that suppress translation of several key proteins regulating the cell cycle. These effects lead to a cell cycle block at the G₁ phase.

In animal models of human cancers, temsirolimus inhibited the growth of a diverse range of cancer types even when an intermittent dosing schedule was used. The compound also appears to have potential for the blockade of inflammatory responses associated with autoimmune and rheumatic diseases by inhibiting T-cell proliferation.

On 11 March 2002, American Home Products changed its name and the name of its subsidiary Wyeth-Ayerst to Wyeth.

During the first half of 2004, Wyeth initiated ongoing recruitment into a US phase III trial comparing orally administered temsirolimus plus letrozole versus letrozole alone as first-line treatment among ≈1200 postmenopausal women with advanced breast cancer. The multicentre, randomised, double-blind, placebo-controlled trial is estimated to last 34 months. All subjects will have the option of participating in the long-term follow-up phase of the trial that involves follow-up every 3 months until disease progression; the primary endpoint is overall progression-free survival.

In August 2004, the US FDA granted temsirolimus fast-track status for the first-line treatment of poor-prognosis patients with advanced renal cell carcinoma.^[1]

Previously in March 2002, temsirolimus received fast-track status from the FDA for the treatment of renal cell carcinoma in patients who failed to respond to interleukin-2 treatment. Wyeth intends to file a NDA for temsirolimus for this indication by 2006.^[2]

Researchers from Wyeth presented the findings from a preclinical study of temsirolimus at the 67th Annual Scientific Meeting of the American College of Rheumatology and the 38th Annual Meeting Association of Rheumatology Health Professionals (ACR/ARHP-2003) [*Orlando, FL, USA; October 2003*]. The aim of this study was to determine the effect of temsirolimus on lymphocyte proliferation and cytokine production. Since lymphocytes and cytokines are significantly involved in the pathogenesis of rheumatoid arthritis, temsirolimus could have

disease-modifying antirheumatic drug (DMARD) activity against rheumatoid arthritis via the inhibition of these factors.^[3]

According to Wyeth's investor presentation in June 2004, the patent covering temsirolimus is due for expiry in 2014.

Table I. Features and properties

Chemical name	[1 <i>R</i> ,9 <i>S</i> ,12 <i>S</i>]1'' <i>R</i> ,3'' <i>R</i> ,4'' <i>R</i>],15 <i>R</i> ,18 <i>R</i> ,19 <i>R</i> ,21 <i>R</i> ,23 <i>S</i> ,30 <i>S</i> ,32 <i>S</i> ,35 <i>F</i>]-1,18-Dihydroxy-12-[2-[4-[3-hydroxy-2-(hydrocyclohexyl)-1-methylethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-d [30.3.1.0(4,9)]hexatriaconta-16(<i>E</i>),24(<i>E</i>),26(<i>E</i>),28(<i>E</i>)-tetraene-2,3,10,14,20-pentaone
Molecular formula	C ₅₆ H ₈₇ N O ₁₆
CAS number	162635-04-3
WHO ATC code	L04A-A (Selective immunosuppressive agents) M01 (Antiinflammatory and Antirheumatic Products) L01D-C (Other cytotoxic antibiotics) N07X (Other Nervous System Drugs)
EphMRA ATC code	M1A (Anti-Rheumatics, Non-Steroidal) N7 (Other CNS Drugs) L1D (Antineoplastic Antibiotics) L4A (Immunosuppressive Agents)
Originator	Wyeth: USA
Highest development phase	Phase II (USA)
Properties	
Mechanism of action	Interferon γ antagonists
Pharmacodynamics	Cytotoxicity in human brain tumour cell lines; tumour growth delay in medulloblastoma and glioblastoma xenografts; reversibly inhibits lymphocyte activation and cytokine production <i>in vitro</i>
Route	IV-infusion
Adverse events	Most Frequent: Drug hypersensitivity, Mucositis, Skin disorders; Occasional: Asthenia, Pruritus; Rare: Diarrhoea, Hypocalcaemia, Vomiting

1. Profile

1.1 Pharmacokinetics

Temsirolimus' pharmacokinetic parameters following weekly treatment have been examined in various studies including a phase I dose-escalation study among 24 patients with cancer at doses from 7.5 to 220 mg/m² and among 16 patients with advanced renal cancer in doses of 25, 75 and 250mg. With increasing dose (25 to 250 mg/m²), temsirolimus exposure in whole blood increased with C_{max} ranging from 595 to 2830 ng/mL and AUC from 1580 to 2700 ng • h/mL. Temsirolimus distribution exceeded total body water and increased with

dose, while Vd_{ss} ranged from 232 to 897L. CL of temsirolimus also increased with dose from 16.1 to 98.0 L/h. Sirolimus, a major metabolite of temsirolimus, exhibited exposures typically exceeding that of the parent drug. Mean t_{1/2} for temsirolimus was 13h and for sirolimus this ranged from 40 to 57h. Data from dose escalation indicated that no advantage in exposure or its variability was gained by using body surface area-normalised dosing, therefore flat dosing was adopted for further clinical development. In addition, no age or gender differences in exposure have been observed to date.^[4,5]

Among the 45 patients with solid tumours receiving temsirolimus 0.75–19.1 mg/m²/day by IV infu-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.